News

Wilex rises after FDA agreement
Enlarge image

BusinessGermany

Wilex rises after FDA agreement

09.10.2012 - German antibody specialist Wilex AG has reached an agreement with the FDA on the further development for its Redectane diagnostic.

According to Wilex, the US regulatory authority accepted the positive vote of an expert committee regarding the clinical usefulness of the test detecting renal tumours. The FDA however demands a second Phase III trial to confirm the diagnostic performance and safety of Redectane. WILEX assumes that an approval can be expected after successful conclusion of this second trial. Originally, the FDA had suggested to run a complex clinical outcomes study to prove the value of Redectane. Dr Paul Bevan, Head of Research and Development, said “eliminating the need for an outcomes-based study – which in our opinion was not a feasible option - will enable us to move forward with our strategy as the regulatory pathway for marketing approval of this innovative imaging agent is now clear. We are delighted with the result.“ 

Redectane is intended to assist in the detection or exclusion of clear cell RCC during diagnostic workup of an intermediate renal mass. Wilex is already conducting preparatory work for the second trial called REDECT 2 and plans to submit the results to the FDA. German antibody specialist Wilex AG has reached an agreement with the FDA on the further development for its Redectane diagnostic. At the Frankfurt Stock Exchange, Wilex was up more than 5% on Monday.

© laborwelt.de/pd

FinancingSwitzerlandUKSwedenGermany

25.04.2014 Crispr Therapeutics has raised US$25m in a series A investment. With the money, the newly formed Swiss biopharma company plans on translating its gene editing technology into medicines for genetic diseases.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • RENEURON (UK)3.60 GBP13.6%
  • EPIGENOMICS (D)5.74 EUR10.4%
  • PROTHENA PLC (IE)36.95 USD9.5%

FLOP

  • CYTOS (CH)0.13 CHF-18.8%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • THERAMETRICS (CH)0.10 CHF-9.1%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.82 EUR39.0%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.13 CHF-95.2%
  • BIONOR PHARMA (N)2.18 NOK-45.5%
  • DIAGENIC (N)0.78 NOK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6275.0%
  • IXICO (UK)67.00 GBP740.7%
  • PLETHORA (UK)10.62 GBP658.6%

FLOP

  • CYTOS (CH)0.13 CHF-96.8%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.95 CHF-71.1%

No liability assumed, Date: 24.04.2014